This is a question that really does go down to the heart of the whole model. Frankly, if we were advancing a model that was lessening the standard upfront, then you would be right to be concerned, but we're not doing that. We need to be very clear here that we want to keep the science uniform upfront. There are some good advances going on in science--new modelling, new statistics--and we can take a look at those good evolutions.
But what we're proposing here is really the merger of science and common sense, because science can say that you could take a long time to resolve certain uncertainties with a drug, and it could take generations for some of it. But you've got to use common sense, because people on therapies need to know things from time to time--caution, don't take with another drug; warning, if you're in this population and you're vulnerable, don't take the drug. So there is this interaction you have to have with the market, and we're trying to do that responsibly. That's what the debate is for us.